Ingredient science ยท molecules and skin
Tranexamic Acid
Tranexamic acid is studied in topical skincare for uneven pigmentation, particularly melasma. Its most interesting feature is a proposed effect on communication between skin cells, rather than exfoliation. Human studies offer both encouraging findings and a useful reminder that the complete preparation and comparison group matter.
A small molecule with two different ends
Tranexamic acid is a synthetic analogue of the amino acid lysine. Its structure contains a six-carbon ring carrying an aminomethyl group and a carboxylic acid group in the trans arrangement. โTransโ describes their relative spatial orientation; the arrangement is part of the moleculeโs identity, not a concentration or product grade. [1]
A cyclohexane framework holds the two attachments.
โCHโโNHโ contains a nitrogen-bearing amine.
โC(=O)โOH contains the acid group.
An acid group is a chemical feature, not a promise of peeling. The surrounding structure determines how a molecule behaves. Tranexamic acid is therefore better understood through its particular molecular interactions than by grouping every ingredient with โacidโ in its name together.
Why water and charge belong in the story
A 2026 physical-chemistry study measured how tranexamic acidโs amine and carboxyl groups gain or lose protons in aqueous solutions. The results depended on temperature and the surrounding salts. This is evidence about solution chemistry, not a clinical pigmentation trial. [3]
A proton is a positively charged hydrogen ion. An amine can accept one, while a carboxylic acid can release one. A molecule bearing both positive and negative groups is called a zwitterion: its total charge may balance even though its individual regions remain charged. This helps explain why โneutral overallโ does not mean โoil-like.โ
How this connects to a serum or cream
Dissolving a substance and delivering it through skin are separate events. Water can surround charged groups, while the outer skin barrier contains lipid-rich regions. A preparation changes the environment at that boundary. Ingredient identity alone does not tell us the amount that reaches a particular skin layer.
How the ingredient is produced
One documented manufacturing route starts with aminomethylbenzoic acid, hydrogenates its ring, converts the resulting isomer mixture toward the trans form, and uses purification and crystallisation to isolate tranexamic acid. This is chemical synthesis, rather than an extraction from a lysine-rich food or plant. [2]
Isomers have the same kinds and numbers of atoms arranged differently. Purification matters here because the ingredient name refers to a particular arrangement. The production story explains identity; it does not turn a manufacturing document into evidence of a skincare effect.
Scientists investigated a conversation between cells
Maeda and Tomita studied pigment-producing human melanocytes with and without medium previously exposed to keratinocytes, the main cells of the epidermis. Tranexamic acid reduced activity of the pigment-making enzyme tyrosinase only when those keratinocyte-derived signals were present. Their experiments implicated the plasminogen/plasmin system in this interaction. [4]
Keratinocytes release substances into their surroundings.
Those substances can change how another cell responds.
Melanocytes alter the activity of pigment-making machinery.
What the culture experiment establishes
The tested range was 0.5โ5 millimolar in cultured cells. The findings support an indirect signalling mechanism rather than direct suppression of isolated melanocytes under those conditions. One author was affiliated with Shiseido. A cell concentration is not a suggested cosmetic use level. [4]
A comparison with hydroquinone showed improvement
A 2019 trial compared a 5% tranexamic acid solution with a 3% hydroquinone cream for 12 weeks. Among 100 adults analysed, melasma severity scores fell by about 27% in both groups. The between-group difference was not statistically significant. This gives a useful human signal, but does not establish that the two treatments are equivalent. [5]
Preparation, participants and limits
The single-blind study enrolled 120 adults; 84 women and 16 men were analysed. Both groups used sunscreen. The tranexamic solution was prepared from pharmaceutical injection material, while the comparator was a cream. Different vehicles, attrition and the absence of a vehicle-only group limit attribution. Three tranexamic-acid participants reported irritation. [5]
A vehicle-controlled trial asked a harder question
In a separate 12-week split-face study, 23 women with epidermal melasma received 5% tranexamic acid gel on one side and its vehicle on the other, alongside sunscreen. Twenty-one completed the trial. Pigmentation improved on both sides, but the tranexamic side was not superior; it also showed significant erythema. This is important evidence against treating every before-and-after improvement as an ingredient effect. [6]
The vehicle is the preparation without the test ingredient. It helps separate an ingredientโs contribution from the base, shared skincare and changes over time. A successful comparison with another active and a negative comparison with a vehicle can coexist: they are different experiments, not interchangeable votes.
Biopsies added a clue about pigment signalling
Kim and colleagues followed 23 women aged 34โ60 using a two-product tranexamic acid regimen. After 12 weeks, melasma scores improved in 22 participants. Biopsies from ten showed reduced epidermal melanin and lower expression of endothelin-1, a local signalling molecule. Vascular changes were trends rather than statistically established reductions. [7]
The actual regimen, not just โa 2% creamโ
Participants used a 2% emulsion twice daily and a mask soaked in 2% lotion three times weekly, with supplied sunblock. Most had mild melasma and all had skin types III or IV. There was no control group, and two authors had Shiseido affiliations. The study links an observed regimen response to tissue measurements without isolating the ingredientโs contribution. [7]
Reading the evidence as a whole
The useful story is a plausible signalling mechanism accompanied by mixed topical findings. A serum label cannot reproduce a trial simply by matching its percentage: gel, solution, emulsion, companion products and the comparison all shape the question being answered. The numbers above describe experiments, not a home-mixing plan.
These studies concern melasma, not every cause of an uneven-looking complexion. Persistent or changing pigmentation merits clinical assessment. Oral and injected tranexamic acid are separate medical routes; their findings and prescribing decisions should not be transferred to a cosmetic topical product.
Sources to follow
- Tranexamic acid molecular identity. Primary chemical identity and trans structure.
- Tranexamic acid scientific documentation. Primary manufacturer process documentation; November 2022.
- Bretti and colleagues, 2026. Primary aqueous acidโbase measurements.
- Maeda and Tomita, 2007. Primary human-cell culture experiment; DOI 10.1248/jhs.53.389.
- Janney and colleagues, 2019. Primary active-comparator trial; full paper reviewed.
- Kanechorn Na Ayuthaya and colleagues, 2012. Primary vehicle-controlled split-face trial; DOI 10.3109/14764172.2012.685478.
- Kim and colleagues, 2016. Primary clinical and biopsy study; DOI 10.1111/ced.12835.
